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EXPLORING THE REGULATORY 
CONTEXT FOR HIV SELF-TESTING & 
PrEP MARKET AUTHORISATION AND 
USE IN NIGERIA 
 
INTRODUCTION 
HIV self-testing and pre-exposure prophylaxis are critical entry 
points for HIV prevention, care, and treatment services 
Pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy 
among people at high risk of contracting HIV.1 Barriers to uptake of PrEP 
include stigma, challenges attending regular clinic visits, adherence, 
medication adverse effects, and the fear of being labelled as HIV positive 
due to the use of antiretrovirals.2  
HIV self-testing (HIVST) has been shown to overcome many of the 
barriers to HIV testing, including stigma, poor access to testing health 
facilities, lack of privacy, and delays in receiving test results.3 Research 
suggests high levels of acceptability and utilisation of oral HIVST in sub-
Saharan Africa, including Nigeria, among subpopulations who may not 
have easy access to conventional testing services.4,5,6 
While significant progress has been made in Nigeria with 
operationalising the implementation of HIVST and PrEP with product 
approvals and inclusion in national guidelines, there is a need to better 
understand how the private sector can optimise delivery, including how 
the market authorisation process and pathways work for HIVST and 
PrEP service delivery in the private sector.  
STUDY AIM 
Funded by the World Health Organization, this study aimed to assess 
HIVST/PrEP availability and market authorisation; determine the 
facilitators and barriers to access; and identify existing systems that 
support the availability, appropriate use, affordability, and accessibility 
in the private sector in Nigeria.  
RECOMMENDATIONS 
• There is urgent need for clarity on 
the registration process for HIVST 
and PrEP as well as the role of the 
National Agency for Food and Drug 
Administration and Control and 
Standards Organisation of Nigeria 
to guide service providers in the 
procurement process for approved 
products.  
• The implementation of the 
National Drug Distribution 
Guidelines should be considered a 
priority to address inconsistences 
in the supply chain and availability 
of HIVST and PrEP. 
• The government should provide 
support to the private sector to 
develop appropriate operational 
manuals and referral pathways/ 
directories at the state level to 
facilitate linkage to care and 
follow-up. 
• It is necessary to streamline the 
authorisation process for 
HIVST/PrEP products in Nigeria to 
minimise barriers and improve 
availability and uptake. 
In September 2020, we conducted an assessment in four geo-political zones in Nigeria: North Central (Abuja-FCT 
and Nasarawa), South South (Rivers), South East (Imo), and South West (Lagos and Ogun). Two local government 
areas in each state, one rural and one urban, were selected. We explored authorisation processes, government 
policies and support systems affecting availability and use of HIVST and PrEP, as well as supply chain, distribution, 
pricing by private sector providers, and linkage to post-test services. We conducted a quantitative survey among 151 
Patent and Proprietary Medicine Vendors (PPMVs) and 136 Community Pharmacists (CPs) recruited by obtaining the 
list of providers from the professional association in the states. Stakeholder dialogues (16) and key informant 
interviews (14) were conducted among government and private sector stakeholders and advocacy groups. Ethical 
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FIGURE 1 HIVST BRANDS SOLD BY PROVIDERS  
 
Other brands include Alere Determine, Swe-Care, Dr.Greg, UniGold, 
3H ViralCheck, Tell, Narrowcare, Global, ProMed, and HealthCheck 
Appropriate sale of HIVST 
Less than half of PPMVs and CPs (45.6%) had a 
standard operating manual for dispensing HIVST, and 
only about one-third had standard guidelines for HIV 
testing services. Although 77% of providers offered 
counselling prior to sale of HIVST, only 23% of CPs and 
13% of PPMVs who offered HIVST reported that their 
facilities were accredited HIV counselling and testing 
centres. About 85% of CPs and 43% of PPMVs reported 
that they perceive their personnel to be knowledgeable 
enough to promote or answer questions on HIVST.  
Pricing 
HIVST was more expensive at CP than PPMV stores. The 
mean price of HIVST from CPs were ₦1138 ($3.0) while 
the mean price among PPMV providers was ₦548 
($1.4). On the other hand, the mean selling price for 
PrEP was ₦3947 ($10.3). There was a consensus 
among providers that service users considered ₦500 
($1.3) an appropriate and affordable price for HIVST. 
Regulatory agencies played a limited role in determining 
the selling price of HIVST and PrEP as this was 
considered the prerogative of the manufacturers. 
‘I think our role is minimal in terms of price 
regulation… our contribution to the overall price of 
the drug is minimal, but nevertheless, … we are 
trying as much as possible to reduce the cost…’ 
Government stakeholders’ dialogue, Lagos 
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KEY FINDINGS 
Registration, authorisation and supply chain for 
HIVST/PrEP in Nigeria 
About 63% of CPs and 27% of PPMVs sold HIVST kits, 
while 15% of CPs and no PPMV sold PrEP in their 
facilities. Most CPs (94%) and 33% of PPMVs who sold 
HIVST kits reported that their facilities were authorised 
to sell HIVST kits.  
• 80% of HIVST providers and 65% of PrEP providers 
checked to see if their products were registered in 
Nigeria. These providers had varied perceptions of 
what constitutes appropriate registration.  
• Although there is a National Drug Policy that outlines 
the authorisation, production, and distribution process 
for medical products and an automated product 
registration system through the National Agency for 
Food and Drug Administration and Control, providers 
reported that the process was cumbersome, time 
consuming, and expensive. 
‘You have to pay fees at various levels... You go to 
somebody’s office “come tomorrow, come today”. 
So, something that would have taken you two days, 
after two months you have not finished, and money 
is running. At every stage, we have bottlenecks...’ 
CP/PPMV dialogue, Abuja-FCT 
The National Drug Distribution Guideline has not been 
implemented, resulting in a poorly coordinated supply 
chain for medical products that impacts the supply of 
quality HIVST and PrEP products in Nigeria. 
‘…The issue of distribution of drug in Nigeria has 
been a thorn in the flesh, it has been defective, it has 
been very chaotic… The national drug distribution 
guideline… has not come into existence because of 
the lack of the necessary political will…’             
CP/PPMV dialogue, Abuja-FCT 
Availability of HIVST/PrEP in Nigeria 
A wide range of HIVST brands were sold by providers. 
The majority of providers procured HIVST and PrEP 
products from sales representatives and pharmacies, 
while  others procured them from the open market and 
non-governmental organisations. Reported challenges 
with the supply of these products include: high costs 
and lack of funds, distance from suppliers, product 
scaricity, and variability in demand. There was 
consensus among stakeholders that lack of awareness 
about HIVST and PrEP in the community contributes to 
the suboptimal demand for these services. As shown in 
Figure 1, there are many HIVST brands sold by 
providers. Providers, however, need to be guided to 
correctly identify and procure products that are fully 
authorised for use in Nigeria. 
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